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Abstract 
The adverse effects or overdose of thiori-
dazine including sudden death, fatal arrhyth-
mia, or retinopathy, in addition to the neuro-
logical signs have been reported. A three-year-
old boy with bronchitis was prescribed eryth-
romycin  by  a  local  clinic,  but  he  started  to
complain  of  severe  drowsiness  and  became
unconscious. It was decided that this was a
result of a compounding error of thioridazine
instead of erythromycin owing to their similar
commercial names. The thioridazine concen-
tration in the child’s serum on admission was
two to three times higher than the Cmax for
adults with the same dosage. The concentra-
tion  of  the  lavage  saline  on  admission  was
only 0.3% of the ingested amount, indicating
that the lavage was not effective in our case.
Pharmacokinetic analysis revealed the param-
eters as Tmax, 1.5 hr; Cmax, 1700 ng/mL; Ka,
2.01 L/hr; Vd, 3.6 L/kg; and T1/2, 6.8 hr. Further
investigations on clinical cases with a phar-
macokinetic analysis should be done to con-
firm the pharmacokinetic evidence obtained
here and to give specific therapeutic guide-
lines for overdose management especially in
children.
Introduction
Thioridazine is a phenotiazine with potent
anxiolytic  and  antipsychotic  properties.
1
Recently  the  adverse  effects  or  overdose  of
thioridazine  including  sudden  death,  fatal
arrhythmia,  retinopathy,  and  neurological
signs and symptoms have been reported.
1-3 We
describe here a case of pediatric thioridazine
toxicity caused by a pharmacy compounding
error. 
Case Report
On  the  morning  of  presentation  to  our
department a three-year-old boy with bronchitis
was prescribed erythromycin by a local clinic.
The  child  took  one  dose  of  the  compounded
drug at the pharmacy at about 13:00, after which
he started to complain of sleepiness and then
became  unconscious.  His  mother  called  the
pharmacy and it was noticed that there was a
compounding error of thioridazine instead of
erythromycin owing to their similar commercial
names. The prescribed drug for the patient was
one-gram of powder per dose (100 mg of thiori-
dazine per dose). The child was transferred to
our hospital and admitted to the pediatric unit. 
On admission he was unconsciousness with
E3, V4, M5 of the Glasgow coma scale. A gastric
lavage was performed and fluid infusion with
intensive monitoring was started. The family
history and the past medical history were unre-
markable. A physical examination revealed a
temperature  of  36.9°C,  blood  pressure  of
119/56 mmHg, pulse of 148 beats/minute, res-
piratory rate of 40 breaths/min, and weight of
13  kg.  A  neurological  examination  revealed
normal  eye  movements  without  nystagmus,
but extensive drowsiness. His pulse oximetry
reading was 100%. An electrocardiogram was
negative for dysrhythmias and elongation QT
intervals. The laboratory investigation includ-
ing a hemogram, serum electrolytes, calcium,
phosphorus,  liver  function  tests,  and  renal
function tests was normal. A brain computed
tomography  (CT)  scan  showed  mild  diffuse
edema. We used 100 mL of 10% glycerol and 10
mg of flosemide. He developed no other severe
symptoms, and he awoke 18 hours after the
dosage but felt mildly sleepy for several hours.
The follow-up ECG and brain CT did not show
any abnormality on the fifth day after admis-
sion. He required no further pharmacological
intervention  for  the  intoxication,  but  was
treated  for  bronchitis  for  the  following  four
days and was discharged in a stable condition. 
The thioridazine concentrations of the spec-
imens were determined by high performance
liquid chromatography (HPLC) compared with
a standard thioridazine preparation of known
concentration  (Sigma  Chemical,  St.  Louis,
MO, USA) using specimens of serum, urine,
and lavage saline. The results showed the pres-
ence  of  a  high  amount  of  thioridazine.  The
thioridazine  concentrations  were  1124.5
ng/mL in the serum on admission, 20.2 ng/mL
in the first urine sample after admission, and
1625.8 ng/mL in 200 mL of the lavage saline on
admission. On the other hand the thioridazine
concentrations  were  277.6  ng/mL,  and  were
not detected in the serum on the next day and
three  days  later.  Pharmacokinetic  analysis
revealed  the  parameters  as  Tmax,  1.5  hr;
Cmax, 1700 ng/mL; Ka, 2.01 L/hr; Vd, 3.6 L/kg;
and T1/2, 6.8 hr (Figure 1).
Discussion 
Thioridazine usage in childhood is rare and
the  information  about  its  pharmacology  and
pharmacokinetics is recognized rarely among
pediatricians.
1-3 The  most  frequent  adverse
effects of thioridazine observed in 159 cases
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Figure  1.  Pharmaco-
kinetic  analysis  of
thioridazine  concen-
tration. Closed circles
indicate  the  observed
values in the serum.
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were impairment of consciousness (98/159),
arrhythmia  and/or  ECG  changes  (68/159),
extrapyramidal symptoms (26/159), confusion
(22/159),  agitation  (19/159),  and  respiratory
disorders  (13/159).  The  correlation  between
the dosage and the degree of cardiovascular
adverse  effects  was  observed.
1 However,  no
information  about  the  serum  concentrations
in these cases was provided. Attention should
be focused on the management of the cardio-
vascular  disturbances  because  of  their  fatal
outcome.
The recommended therapeutic approaches
for  the  overdose  of  thioridazine  are  gastric
lavage, administration of activated charcoal to
eliminate the drug, and securing an open air-
way  in  unconscious  patients.  The  solution
from  the  gastric  lavage  at  six  hours  after
ingestion had a concentration of 1625.8 ng/mL,
which is a total of 325 μg in 200 mL saline.
This total amount is only 0.3% of the ingested
amount  indicating  that  the  lavage  was  not
effective  in  our  case  possibly  because  the
absorption phase was completed, as indicated
in Figure 1. Although we could not measure
the  sulfoxide  and  sulfonated  metabolites  of
thioridazine, they have similar effects to the
thioridazine itself and their elimination from
the body is prolonged.
4,5 
The values obtained from the adults who took
200 mg of the drug showed the values as Tmax,
3.3 hr; Cmax, 750 ng/mL; Ka, 2.11 L/hr; Vd, 3.5
L/kg; and T1/2, 7.5 hr; indicating that the phar-
macokinetics in children generally can be treat-
ed as those in the adults, except for the absorp-
tion phase.
4,5 However, Cmax should be much
higher than those of the adults owing to the
higher dosage per body weight, having a high
risk for adverse effects.
4-6 In addition the lavage
may  not  be  effective  after  one  hour  possibly
because  of  its  quick  absorption  kinetics  in
infants  compared  to  that  in  adults.  Further
investigations on clinical cases with a pharma-
cokinetic analysis should be done to confirm the
pharmacokinetic evidence obtained in our case
and to give specific therapeutic guidelines for
overdose management especially in children.
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